Publisher's latest report ‘Global Orphan and Rare Dermatology Drugs Market to 2024’ identifies the changing trends in the orphan and rare dermatology drugs market with particular focus on systemic sclerosis (scleroderma), alopecia, epidermolysis bullosa, pemphigus vulgaris, vitiligo and cutaneous lupus erythematosus.
Philippa Salter, Analyst for Publisher, commented: “Many orphan and rare dermatology disorders are associated with significant quality of life impairments, particularly if the disease is insufficiently controlled. However, the current therapeutics market is a highly genericized therapy area and therefore small, but this is set to change as many new products will enter the market during the forecast period, including treatments for diseases that currently have no effective treatment options.”
The number of companies with a market share in the orphan and rare dermatology therapy area is expected to more than double over the forecast period, according to Publisher.
Salter explains: “Many of the companies which are entering
the orphan and rare dermatology market over the forecast period are smaller
companies with more specialized product portfolios. In 2017 only one company
was generating more than 10% of its overall revenue from the orphan and rare
dermatology therapy area. However, by 2024 there will be several companies generating
more than 85% of their revenue from the therapy area.”
Salter added: “Across orphan and rare dermatological diseases, there is a strong need for innovation and development of effective disease-modifying drugs. This is reflected by the pipeline of 262 active products for orphan and rare dermatology diseases, which is reasonably large considering how rare most of the disorders are.”